Medtronic Neurovascular Names Dr. Adam Arthur Chief Medical Officer

Medtronic Neurovascular, a company focused on stroke care, has appointed Dr. Adam S. Arthur as its new chief medical officer. Dr. Arthur will take office on September 30, 2025.

Dr. Arthur boasts over two decades of experience as a practicing neurosurgeon and previously served as the chair of neurosurgery at the University of Tennessee Health Science Center. He has leadership in clinical trials and a commitment to innovation that Medtronic said improved stroke patients’ outcomes and advanced the field of neurovascular care.

“It’s an exciting time to be a part of the Neurovascular team as we focus on creating future breakthroughs in stroke care,” said Linnea Burman, president of Medtronic Neurovascular. “I’m confident Dr. Arthur will play an important role in advancing our goal of helping more stroke patients access world-class neurovascular care.”

In his new role, Dr. Arthur will guide development strategy, bolster Medtronic’s relationships with physicians, and further the commitment to improving outcomes. He said he will devote part of his time to patient care in his Semmes Murphey practice and stay on the University of Tennessee’s Health Science Center’s College of Medicine faculty.

“I’m excited and honored to join the team at Medtronic Neurovascular as chief medical officer,” said Dr. Arthur. “My top priority is improving care for patients, and this role allows me to be closer to the innovations that will deliver better patient outcomes.”

Last week, Medtronic announced it had earned U.S. Food and Drug Administration (FDA) approval for its Altaviva minimally invasive implantable tibial neuromodulation (ITNM) device therapy for urinary urge incontinence.